ONESOURCE SPECIALTY PHARMA Financial Statement Analysis
|
||
|
The Revenues of ONESOURCE SPECIALTY PHARMA have increased by 344.07% YoY .
The Earnings Per Share (EPS) of ONESOURCE SPECIALTY PHARMA has decreased by Negative YoY. |
||
ONESOURCE SPECIALTY PHARMA Last 5 Annual Financial Results
[BOM: 544292|NSE : ONESOURCE]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|
| Revenues | ₹172 Cr | ₹39 Cr | ₹128 Cr | ₹128 Cr |
| Expenses | ₹260 Cr | ₹199 Cr | ₹132 Cr | ₹132 Cr |
| Operating Profit (Excl OI) | ₹-88 Cr | ₹-161 Cr | ₹-4.01 Cr | ₹-4.01 Cr |
| Other Income | ₹4.23 Cr | ₹2.69 Cr | ₹3.67 Cr | ₹3.67 Cr |
| Interest | ₹89 Cr | ₹48 Cr | ₹46 Cr | ₹46 Cr |
| Depreciation | ₹76 Cr | ₹66 Cr | ₹53 Cr | ₹53 Cr |
| Profit Before Tax | ₹-366 Cr | ₹-416 Cr | ₹-100 Cr | ₹-100 Cr |
| Profit After Tax | ₹-366 Cr | ₹-416 Cr | ₹-100 Cr | ₹-100 Cr |
| Consolidated Net Profit | ₹-391 Cr | ₹-800 Cr | ₹-231 Cr | ₹-231 Cr |
| Earnings Per Share (Rs) | ₹-1.57 | ₹-97.55 | ₹-199.46 | ₹-76.14 |
| PAT Margin (%) | -1.20 | -212.71 | -1,073.63 | -77.86 |
| ROE(%) | -0.55 | -62.66 | -46.39 | -9.86 |
| ROCE(%) | 2.61 | -21.41 | -19.43 | -2.46 |
| Total Debt/Equity(x) | 0.13 | 1.45 | 1.07 | 1.14 |
Key Financials |
||
| Market Cap | : | ₹ 17,374.8 Cr |
| Revenue (TTM) | : | ₹ 1,543.3 Cr |
| Net Profit(TTM) | : | ₹ -48.6 Cr |
| EPS (TTM) | : | ₹ -4.2 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ONESOURCE SPECIALTY PHARMA | 0.2% | -6.6% | -18.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 2% | -1.7% | 15.9% |
| DIVIS LABORATORIES | 6.5% | 14.8% | 48.4% |
| TORRENT PHARMACEUTICALS | 1.2% | -2.5% | 37.2% |
| CIPLA | -0.3% | -3.9% | -11.4% |
| DR REDDYS LABORATORIES | -2.2% | 1.5% | -8.3% |
| MANKIND PHARMA | 1.4% | -2.9% | -6.7% |
| LUPIN | 0.1% | -9.8% | 10.7% |
| ZYDUS LIFESCIENCES | 2.8% | 3.2% | 16% |
ONESOURCE SPECIALTY PHARMA Revenues
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | 344.07 % |
| 5 Yr CAGR | 10.28 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹172 Cr | 344.07 | |
| Mar2024 | ₹39 Cr | -69.80 | |
| Mar2023 | ₹128 Cr | 0.00 | |
| Mar2022 | ₹128 Cr | - | |
ONESOURCE SPECIALTY PHARMA Operating Profit
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹-88 Cr | Negative | |
| Mar2024 | ₹-161 Cr | Negative | |
| Mar2023 | ₹-4.01 Cr | Negative | |
| Mar2022 | ₹-4.01 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | -51.33% | Negative | |
| Mar2024 | -415.06% | Negative | |
| Mar2023 | -3.13% | Negative | |
| Mar2022 | -3.13% | - | |
ONESOURCE SPECIALTY PHARMA Profit After Tax
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹-391 Cr | Negative | |
| Mar2024 | ₹-800 Cr | Negative | |
| Mar2023 | ₹-231 Cr | Negative | |
| Mar2022 | ₹-231 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | -1.2 % | Negative | |
| Mar2024 | -212.71 % | Negative | |
| Mar2023 | -1073.63 % | Negative | |
| Mar2022 | -77.86 % | - | |
ONESOURCE SPECIALTY PHARMA Earnings Per Share (EPS)
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹-1.57 | Negative | |
| Mar2024 | ₹-98 | Negative | |
| Mar2023 | ₹-199 | Negative | |
| Mar2022 | ₹-76 | - | |
ONESOURCE SPECIALTY PHARMA Return on Capital Employed (ROCE)
[BOM: 544292|NSE : ONESOURCE]
| Y-o-Y | Positive |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 2.61% | Positive | |
| Mar2024 | -21.41% | Negative | |
| Mar2023 | -19.43% | Negative | |
| Mar2022 | -2.46% | - | |
ONESOURCE SPECIALTY PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,514.8 |
| Current MarketCap | : | ₹ 17,374.8 Cr |
| Updated EOD on | : | Aug 31,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ONESOURCE SPECIALTY PHARMA | 0.2% |
-6.6% |
-18.6% |
| SENSEX | -0.5% |
-1.3% |
-5.4% |
ONESOURCE SPECIALTY PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2% | 1.7% | 15.1% |
| BSE SELECT IPO INDEX | 0.3% | 4.8% | -1.3% |
| BSE 400 MIDSMALLCAP INDEX | 0% | 2.3% | 7.6% |
| BSE 250 SMALLCAP INDEX | -0.1% | 2.8% | 6% |
| BSE 1000 | -0.4% | 0.6% | 2.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 1.7% | 1.4% | 17.4% |
| NIFTY MIDSMALLCAP 400 | 0.3% | 2.5% | 9% |
| NIFTY MIDSMALLCAP400 50:50 | 0.2% | 2.6% | NA |
| NIFTY SMALLCAP 500 | 0.2% | 4% | NA |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0% | 1.5% | 5.6% |
You may also like the below Video Courses
FAQ about ONESOURCE SPECIALTY PHARMA Financials
How the annual revenues of ONESOURCE SPECIALTY PHARMA have changed ?
The Revenues of ONESOURCE SPECIALTY PHARMA have increased by 344.07% YoY .
How the Earnings per Share (EPS) of ONESOURCE SPECIALTY PHARMA have changed?
The Earnings Per Share (EPS) of ONESOURCE SPECIALTY PHARMA has decreased by Negative YoY .
Check out Intrinsic Value of Peers of ONESOURCE SPECIALTY PHARMA
Compare Stock Analytics of Peers of ONESOURCE SPECIALTY PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
